

Caris Pharmatech Studies

Sponsor	Protocol Number	Biomarkers	Indication	Study Phase	Study Drug	Protocol Title
Merus N.V.	MCLA-128-CL01	NRG1	Solid Tumors	2	MCLA-128	A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
Curegenix	CGX1321-101	RSPO2, RSPO3, RNF43, BRAF V600E	GI solid tumors	1	CGX1321	A Phase 1 Open-label Dose Escalation Study of CGX1321 Subjects with Advanced Solid Tumors with Expansion in Advanced Gastrointestinal Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Colorectal Cancer or in Combination with Encorafenib + Cetuximab in Subjects with BRAF V600E Mutated Advanced Colorectal Cancer
IDEAYA Biosciences	IDE196-001	GNAQ, GNA11	Solid tumors	2	IDE196	A phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusions
Mirati Therapeutics	849-001	KRAS G12C, STK 11	Solid Tumors	1/2	MRTX849	A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Mirati Therapeutics	849-007	KRAS G12C	NSCLC	2	MRTX849 and Pembrolizumab	A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Mirati Therapeutics	849-010	KRAS G12C	CRC	3	Adagrasib (MRTX849), Cetuximab (ERBITUX®), 5-Fluorouracil Irinotecan Oxaliplatin Folinic Acid	A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

CONFIDENTIAL

This report is confidential and proprietary to Caris, Inc. Be aware that any disclosure, copying, distribution, or use of the contents of this report is prohibited. The contents of this document may not be disclosed to any other person or entity outside of your site without prior written permission of Caris, Inc.

For more detailed information about each clinical trial, visit [TrialPlus.CarisLS.com](https://www.trialplus.carisls.com).

Sponsor	Protocol Number	Biomarkers	Indication	Study Phase	Study Drug	Protocol Title
Roche	BO41932	NTRK, ROS1, ALK, AKT, PIK3CA, BRAF II/III, RET	Advanced solid tumors	2	Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab, Emtansine, GDC-0077	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Relay	RLY-4008-101	FGFR2 alterations	Cholangiocarcinoma and solid tumors	1	RLY-4408	A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Rain Therapeutics	3202	Wild-type (WT) TP53 and MDM2	Solid Tumors	2	Milademetan (RAIN-32)	A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors
Day One	DAY 101-102	BRAF Fusions, CRAF/RAF1 Fusions and Amplifications	Melanoma or other solid tumors	2	DAY101	A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors and MAPK Pathway Aberrations
Pyramid Biosciences	PBI-200-101	NTRK-fusion-positive or NTRK-amplified, EWSR1-WT1-fusion-positive	Solid Tumors	1/2	PBI-200-101	PBI-200-101 A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors

CONFIDENTIAL

This report is confidential and proprietary to Caris, Inc. Be aware that any disclosure, copying, distribution, or use of the contents of this report is prohibited. The contents of this document may not be disclosed to any other person or entity outside of your site without prior written permission of Caris, Inc.

For more detailed information about each clinical trial, visit [TrialPlus.CarisLS.com](https://www.trialplus.carisls.com).

Sponsor	Protocol Number	Biomarkers	Indication	Study Phase	Study Drug	Protocol Title
Redx Pharma Plc	RXC004/0002	RNF43 or RSPO2, RSPO3	Metastatic MSS CRC	2	RXC004	A Multi-arm, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy of RXC004 in Monotherapy and in Combination with Nivolumab, in Patients with Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer who have Progressed following Therapy with Current Standard of Care
Fore Biotherapeutics	F8394-201a	BRAF	Solid tumors with BRAF fusions	2	FORE8394	A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
Kinnate Biopharma	KN-8701	BRAF Class II and III; Melanoma NRAS mutations	Solid tumors harboring BRAF Class II or III mutations or melanoma with NRAS mutation; Advanced/ Metastatic	1	KIN2787	A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors
Endeavor	ENV-ONC-101	PTCH1	Solid Tumors with PTCH1 Mutations	2	ENV-101	A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
BriaCell	BRI-ROL-001	HER2+, HER2-, ER+, PR+, ER-, PR-, TNBC	Breast Cancer	2	SV-BR-1-GM,	A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with Retifanlimab

CONFIDENTIAL

This report is confidential and proprietary to Caris, Inc. Be aware that any disclosure, copying, distribution, or use of the contents of this report is prohibited. The contents of this document may not be disclosed to any other person or entity outside of your site without prior written permission of Caris, Inc.
For more detailed information about each clinical trial, visit [TrialPlus.CarisLS.com](https://www.trialplus.carisls.com).

Sponsor	Protocol Number	Biomarkers	Indication	Study Phase	Study Drug	Protocol Title
AADI Bioscience	TSC-007	TSC1; TSC2	solid tumor	2	ABI-009 nab-sirolimus	A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Fore Biotherapeutics	F8294-201b	BRAF V600E	CNS tumors with BRAF V600E alteration	2	FORE8394	A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
Boehringer Ingelheim	1403-0008	MDM2 amplifications	Dedifferentiated Liposarcoma	2	BI 907828	Brightline-1: A Phase II/III, randomized, open-label, multi-centre study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
Boehringer Ingelheim	1403-0011	MDM2 amplification	Biliary tract adenocarcinoma OR Pancreatic ductal adenocarcinoma	2	BI 907828	Brightline 2- A Phase II/III, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type solid tumours-biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors
Apollomics, Inc	APL-101-01	c-Met	Locally advanced or metastatic solid tumors	2	APL-101	A Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

CONFIDENTIAL

This report is confidential and proprietary to Caris, Inc. Be aware that any disclosure, copying, distribution, or use of the contents of this report is prohibited. The contents of this document may not be disclosed to any other person or entity outside of your site without prior written permission of Caris, Inc.

For more detailed information about each clinical trial, visit [TrialPlus.CarisLS.com](https://www.trialplus.carisls.com).